|
1. Biologie
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Approving new drugs [Science]
|
|
|
|
|
|
Over
the years, the FDA has learned that, for many diseases, it is important
that the drug maker prove the benefits of the drug before unleashing it
on the public. Does this slow the process and greatly add to the
R&D costs? Absolutely. But it is good medical practice.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
5 ways to improve care at the end of life [STAT]
|
|
|
|
|
|
We
had the honor of chairing the Aspen Health Strategy Group, composed of
23 experienced leaders in health care, technology, and the media, as it
explored ways to improve care at the end of life. Here are five of the
transformative ideas we included in the group’s report.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|